Cargando…
SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway
BACKGROUND: Optimal therapeutic strategies for hepatocellular carcinoma (HCC) patients are still challenging due to the high recurrence rate after surgical resection and chemotherapy resistance. Growing evidence shows that genetic and epigenetic alterations are involved in HCC progression and resist...
Autores principales: | Zhao, Jie, Wozniak, Ann, Adams, Abby, Cox, Josiah, Vittal, Anusha, Voss, Jordan, Bridges, Brian, Weinman, Steven A., Li, Zhuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567523/ https://www.ncbi.nlm.nih.gov/pubmed/31196136 http://dx.doi.org/10.1186/s13046-019-1246-4 |
Ejemplares similares
-
Elevated blood monocyte counts in alcohol‐associated hepatitis
por: Voss, Jordan K., et al.
Publicado: (2022) -
Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation
por: Zeng, Zhen, et al.
Publicado: (2012) -
SIRT7 Deacetylates STRAP to Regulate p53 Activity and Stability
por: Yu, Miao, et al.
Publicado: (2020) -
The complex role of SIRT7 in p53 stabilization: nucleophosmin joins the debate
por: Kumari, Poonam, et al.
Publicado: (2021) -
Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer
por: Zhang, Chen, et al.
Publicado: (2022)